VLON - Vallon stock surges on review of strategic alternatives

Vallon Pharmaceuticals (NASDAQ:VLON) shares surged ~80% Friday morning after the biopharmaceutical firm announced review of strategic alternatives to maximize shareholder value. Vallon engaged financial services company Ladenburg Thalmann to evaluate strategic alternatives for the company that could include the potential for a possible merger, business combination, investment into the company, or a purchase, license or other acquisition of assets. In the meantime, the company is also streamlining its operations to preserve its capital and cash resources. VLON shares have slumped 75.27% over the past year and are down 84.04% YTD. Previously (in Mar): Vallon crashed after lead program for ADHD candidate did not meet main goal

For further details see:

Vallon stock surges on review of strategic alternatives